Original Article

You have free access to this content

Immunophenotyping is an independent factor for risk stratification in AML

  1. R. Repp1,*,
  2. U. Schaekel2,
  3. G. Helm1,
  4. C. Thiede2,
  5. S. Soucek2,
  6. U. Pascheberg3,
  7. H. Wandt4,
  8. W. Aulitzky5,
  9. H. Bodenstein6,
  10. R. Sonnen7,
  11. H. Link8,
  12. G. Ehninger2,
  13. M. Gramatzki1

Article first published online: 21 APR 2003

DOI: 10.1002/cyto.b.10030

Issue

Cytometry Part B: Clinical Cytometry

Cytometry Part B: Clinical Cytometry

Special Issue: Cytomics in Predictive Medicine

Volume 53B, Issue 1, pages 11–19, May 2003

Additional Information

How to Cite

Repp, R., Schaekel, U., Helm, G., Thiede, C., Soucek, S., Pascheberg, U., Wandt, H., Aulitzky, W., Bodenstein, H., Sonnen, R., Link, H., Ehninger, G. and Gramatzki, M. (2003), Immunophenotyping is an independent factor for risk stratification in AML. Cytometry, 53B: 11–19. doi: 10.1002/cyto.b.10030

Author Information

  1. 1

    Department of Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany

  2. 2

    Department of Medicine I, University of Dresden, Dresden, Germany

  3. 3

    Dortmund, Germany

  4. 4

    Department of Medicine V, Klinikum Nuremberg, Nuremberg, Germany

  5. 5

    Department of Medicine II, Robert-Bosch Hospital, Stuttgart, Germany

  6. 6

    Department of Hematology/Oncology, Klinikum Minden, Minden, Germany

  7. 7

    Department of Hematology, Krankenhaus St. Georg, Hamburg, Germany

  8. 8

    Department of Medicine I, Westpfalz-Klinikum, Kaiserslautern, Germany

*Division of Hematology/Oncology, Department of Medicine III, Krankenhaustrasse 12, 91054 Erlangen, Germany

Publication History

  1. Issue published online: 21 APR 2003
  2. Article first published online: 21 APR 2003
  3. Manuscript Accepted: 14 FEB 2003
  4. Manuscript Received: 13 JAN 2003

Funded by

  • Deutsche Krebshilfe

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

Keywords:

  • acute myeloid leukemia AML;
  • immunophenotyping;
  • prognosis;
  • risk factors;
  • statistics;
  • retrospective study;
  • multicenter study

Abstract

Background

Chromosomal abnormalities are one of the most important prognostic factors in acute myeloid leukemia (AML). However, only a limited number of patients have such informative chromosomal abnormalities. The prognostic value of immunophenotyping in this disease is still unclear.

Methods

Seven hundred and eighty-three newly diagnosed AML patients treated in the German SHG-AML trials in 1991 and 1996 were analyzed with a panel of 33 antibodies. Expression was correlated to overall survival, complete remission-rate, and complete remission duration, and tested in a multivariate analysis including other clinical and biological markers.

Results

With a median follow-up of 4.3 years, patients with AML blasts negative for CD9, CD11b, CD13, CD34, and CD41, or positive for CD15, CD33, CD38, CD64, and MPO had superior overall survival. This effect was associated with a significantly higher complete remission rate (CD13, CD34, CD41, and CD64) or a longer complete remission duration (CD9, CD11b, and CD64). Cox-regression analysis, including cytogenetic, morphologic, and biologic parameters showed CD9, CD13, CD34, and CD64 as independent factors for overall survival. These markers were used for a prognostic score. Patients were pooled in three groups with highly significant differences of overall survival. The prognostic relevance of this score was confirmed in patients with normal karyotype and/or in younger patients ≤ 60 years.

Conclusions

Immunophenotyping is not only helpful for diagnosis but is of independent significance for prognosis, and may be useful for risk stratification in AML patients. Cytometry Part B (Clin. Cytometry) 53B:11–19, 2003. © 2003 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (132K)